The influence of penetration enhancers on the volume instilled of eye drops

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 45, Issue 2, 1998, Pages 189-198

  Van Santvliet, Luc ^a   Ludwig, Annick ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Drop size; Ophthalmic formulation; Penetration enhancer; Solution acceptability; Surface tension

Indexed keywords

DEOXYCHOLATE SODIUM; EYE DROPS; OCTYL GLUCOSIDE; PENETRATION ENHANCING AGENT; POLIDOCANOL; POLYOXYETHYLENE STEARYL ETHER; POLYSORBATE 80; TYLOXAPOL;

ARTICLE; DRUG FORMULATION; HUMAN; PATIENT; PHYSICAL CHEMISTRY; QUESTIONNAIRE; SURFACE TENSION;

CHEMISTRY, PHARMACEUTICAL; OPHTHALMIC SOLUTIONS; PHARMACEUTIC AIDS; SURFACE-ACTIVE AGENTS;

EID: 0031960963     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(97)00114-8     Document Type: Article

References (32)

1. Lee V., Robinson J. Review: topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2:1986;67-108.
2. Urtti A., Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37:1993;435-456.
3. Järvinen K., Järvinen T., Urtti A. Ocular absorption following topical delivery. Adv. Drug Del. Rev. 16:1995;3-19.
4. Saettone M., Giannaccini B., Ravecca S., La Marca F., Tota G. Polymer effects on ocular bioavailability - the influence of different liquid vehicles on the mydriatic response of tropicamide in humans and in rabbits. Int. J. Pharm. 20:1984;187-202.
5. Ludwig A., Van Ooteghem M. The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans. Int. J. Pharm. 54:1989;95-102.
6. Greaves J., Wilson C. Treatment of diseases of the eye with mucoadhesive delivery systems. Adv. Drug Del. Rev. 11:1993;349-383.
7. Zimmer A., Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Del. Rev. 16:1995;61-73.
8. Meisner D., Mezei M. Liposome ocular delivery systems. Adv. Drug Del. Rev. 16:1995;75-93.
9. Saettone F., Chetoni P., Cerbai R., Mazzanti G., Baghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity. Int. J. Pharm. 142:1996;103-113.
10. Hochman J., Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J. Control. Rel. 29:1994;253-267.
11. Sasaki H., Igarashi Y., Nagano T., Nishida K., Nakamura J. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm. Res. 12:1995;1146-1150.
12. Chiou G. Systemic delivery of polypeptide drugs through ocular route. Annu. Rev. Pharmacol. Toxicol. 31:1991;457-467.
13. Chiou G., Shen Z., Zheng Y., Chen Y. Enhancement of systemic delivery of peptide drugs via ocular route with surfactants. Drug Dev. Res. 27:1992;177-183.
14. Pillion E., Atchison J., Stott J., McCracken D., Gargiulo C., Meezan E. Efficacy of insulin eyedrops. J. Ocul. Pharmacol. 10:1994;461-470.
15. Mishima S., Gasset A., Klyce S., Baum J. Determination of tear volume and tear flow. Inv. Ophthalmol. 5:1966;264-276.
16. Lederer C., Harold R. Drop size of commercial glaucoma medications. Am. J. Ophthalmol. 101:1986;691-694.
17. Salminen L. Review: systemic absorption of topically applied ocular drugs in humans. J. Ocul. Pharmacol. 6:1990;243-249.
18. Flach A. Systemic toxicity associated with topical ophthalmic medications. J. Florid M. A. 81:1994;256-260.
19. Shell J. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 26:1982;207-218.
20. Petursson G., Cole R., Hanna C. Treatment of glaucoma using minidrops of clonidine. Arch. Ophthalmol. 102:1984;1180-1181.
21. Van Hunsel J., Bleys G., Joos P. Adsorption kinetics at the oil/water interface. J. Colloid Interface Sci. 114:1986;432-441.
22. L. Van Santvliet, A. Ludwig, Statistical analysis of the weight of drops delivered from flexible dropper bottles, Proc. 14th Pharm. Techn. Conf. 1a (1995) 486-494.
23. Ludwig A., Van Ooteghem M. Influence of viscolyzers on the residence of ophthalmic solutions evaluated by slit lamp fluorophotometry. STP Pharma Sci. 2:1992;81-87.
24. Holly F., Patton J., Dohlman C. Surface activity determination of aqueous tear components in dry eye patients and normals. Exp. Eye Res. 24:1977;479-491.
25. Goode S., Sandborn G. Effect on mydriasis of modifying of phenylephrine drops. Br. J. Ophthalmol. 75:1991;222-223.
26. Brown R., Hotchkiss M., Davis B. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am. J. Ophthalmol. 99:1985;460-464.
27. Fraunfelder F., Meyer M. Systemic side effects from ophthalmic timolol and their prevention. J. Ocul. Pharmacol. 3:1987;177-184.
28. Marsh R., Maurice D. The influence of non-ionic detergents and other surfactants on human corneal permeability. Exp. Eye Res. 11:1971;43-48.
29. Tiffany J., Winter N., Bliss G. Tear film stability and tear surface tension. Curr. Eye Res. 8:1989;507-515.
30. Chiou G., Li B. Chronic systemic delivery of insulin through the ocular route. J. Ocul. Pharmacol. 9:1993;85-90.
31. Ludwig A., Van Haeringen N., Bodelier V., Van Ooteghem M. Relationship between precorneal retention of viscous eye drops and tear fluid composition. Int. Ophthalmol. 16:1992;23-26.
32. Jahro P., Järvinen K., Urtti A., Stella V., Järvinen T. Modified beta-cyclodextrin (SBE7-betaCYD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine produg in rabbits. J. Pharm. Pharmacol. 48:1996;263-269.